News for hackers. Stuff that matters.
Re:I am dying of squamous cell carcinoma, and potential trea... by melling on Saturday July 22, 2023 @12:59PM (#36827812)
This has been a common complaint for decades. We always want to try rush experimental drugs/procedures that “show promise”.

How often do these drugs, etc turn out to effective? 25 years ago we wanted to rush gene therapy and that didn’t turn out well. Someone died. It probably set back gene therapy:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC81135/

I think the solution is to invest more into medical research now, then when we, or someone we know, eventually ends up with some horrible disease, (cancer(s), Alzheimer’s, Parkinson’s, etc) we’ll know that we at least we made significant effort, and gave everyone a better chance, rather than settle for a “Hail Mary” drug near the end.

Re:I am dying of squamous cell carcinoma, and potential trea... by appplication on Saturday July 22, 2023 @01:11PM (#36827904)
> we’ll know that we at least we made significant effort, and gave everyone a better chance, rather than settle for a “Hail Mary” drug near the end.

I think this is a sensible take for someone who is not facing their own imminent mortality. But no matter what we do, the game theory of terminal diagnoses means there will always be incentive to go for a Hail Mary in the end.

Re:I am dying of squamous cell carcinoma, and potential trea... by fallingknife on Saturday July 22, 2023 @01:35PM (#36828080)
3 years ago we wanted to rush the COVID vaccine and it probably saved millions.

I don't understand why we can't let people make risk reward judgments. Yes probably more people will die, but they were not forced.

Re:I am dying of squamous cell carcinoma, and potential trea... by EatingWithForks on Saturday July 22, 2023 @01:41PM (#36828122)
The COVID vaccine already had an existing model to work from that was already ready to go and approved in the SARS-COV-1 vaccine nearly a decade earlier.
Re:I am dying of squamous cell carcinoma, and potential trea... by torstenvl on Saturday July 22, 2023 @01:36PM (#36828091)
I agree. Dying in anguish at the hands of your own government is far worse than dying having tried everything you could.
Re:I am dying of squamous cell carcinoma, and potential trea... by inhumantsar on Saturday July 22, 2023 @02:00PM (#36828274)
I agree with you but I also understand the argument that being given the choice between certain death and uncertain death is a form of coercion
Re:I am dying of squamous cell carcinoma, and potential trea... by fallingknife on Saturday July 22, 2023 @05:05PM (#36829936)
And I'm sure that those people dying are saying to themselves "well at least I wasn't coerced"
Re:I am dying of squamous cell carcinoma, and potential trea... by lucianbr on Saturday July 22, 2023 @02:36PM (#36828572)
Did you never experience the situation where someone you care about is making a choice you think is wrong, and you want to protect them from themselves?

I'm not saying this is the right thing to do. I'm just trying to explain how it happens. People don't make good risk judgements in general, and other people think that it is good to do good by force. This is why seat belts are mandatory, smoking is discouraged, drugs are illegal, public companies traded on exchanges are strongly regulated, and so on and so forth.

> Yes probably more people will die

You really don't understand why we choose the option where less people die? We value life, I guess.

Re:I am dying of squamous cell carcinoma, and potential trea... by EA-3167 on Saturday July 22, 2023 @01:03PM (#36827854)
People are, perhaps understandably, very eager to advance at a faster pace, always a faster pace. Nowhere is that more evident than in the case of people facing death regardless, but in addition to the issues you raised (early failures can lead to even worse delays) there are other ethical concerns. Terminally ill people are often understandably desperate, and I would be too in their position, no doubt about it. Their families are desperate, often their doctors are desperate. That doesn't mean that their remaining life doesn't have value though, or that cutting it weeks, months or years short isn't a problem.

I think that's often lost on people, and in a more frightening way, people who are all-to-eager to use the terminally ill as ultimately disposable test subjects for unproven treatments. If it was JUST down to safety then I could see the point to an extent, but as you said efficacy is a big open question too. Of course if you're facing death then you may well want to roll the dice, but the question there too is how well you really understand the odds. The understandable implication in a lot of the discussions around this issue is that if only regulators were a bit faster, people like the author wouldn't die.

The reality is grim though, most of these experimental drugs and therapies are not effective, regardless of whether or not they're safe.

Re:I am dying of squamous cell carcinoma, and potential trea... by causality0 on Saturday July 22, 2023 @01:16PM (#36827950)
We let people have assisted-suicide for reasons from homelessness to hearing loss, twenty thousand people a year. Why do we respect their self-ownership when they're trying to die but not when they're trying not to die? Why do we get to decide what is and isn't worth the risk?
Re:I am dying of squamous cell carcinoma, and potential trea... by EA-3167 on Saturday July 22, 2023 @01:18PM (#36827967)
Because they're trying to die, they're literally getting what they want, guaranteed. Having said that I don't agree with assisted suicide for the reasons you listed. Either way it's not as though people seeking death are being mislead as to the odds, are engaging in desperate reasoning that they'll be the lucky ones who get to live a bit longer.

You offer someone death, they get death.

This is about people desperate for cures and treatments that probably won't work, and may well give them the opposite outcome from what they hope for.

There is a difference in kind.

Re:I am dying of squamous cell carcinoma, and potential trea... by causality0 on Saturday July 22, 2023 @01:29PM (#36828031)
Either way it's not as though people seeking death are being mislead as to the odds, are engaging in desperate reasoning that they'll be the lucky ones who get to live a bit longer

This applies just as much to approved treatments as unapproved, for the same reasons, and has the exact same solutions such as having a third party with no vested interests explain to the patient. In fact it has those problems less than approved treatments because the companies are being paid by the insurance company for the approved treatments but not the experimental ones.

Re:I am dying of squamous cell carcinoma, and potential trea... by EA-3167 on Saturday July 22, 2023 @01:31PM (#36828051)
The key is that the approved treatments are proven to have the requisite efficacy, the risks that come with that are an acceptable tradeoff. The unapproved, often largely untested world of early breakthroughs doesn't have that guarantee of potential efficacy, it often JUST has risks.
Re:I am dying of squamous cell carcinoma, and potential trea... by tux3 on Saturday July 22, 2023 @01:51PM (#36828195)
It may help to not view the options as a binary choice between drugs approved under the current process and any drug not currently approved.

What constitutes the acceptable tradeoff is the heart of the matter. On the one hand, even the current approval process does not always guarantee efficacy (Aduhelm to mention it by name). Medical trials work with considerable uncertainty, and the risk/benefit tradeoff is always a question of probabilities. Even with the current process, there is no certainty or guarantee.

It is possible to take those probabilities and to talk about the expected number needed to treat (NNT) for a medication, the expected side effect profile, how many people might live and how many might die. Things that may sound cold, but that are already routinely done today.

It is hard to know where the tradeoff should be, how much margin of error is the right amount before something is approved, knowing that there is uncertainty even in large trials, but it's not a choice between the totally unapproved and the status quo. (Better yet, we should not model the choice as a single parameter that goes from more choice & more snake oil to less choice & more safety. It's also often possible to improve one aspect of a bureaucracy without it being a zero-sum game.)

Re:I am dying of squamous cell carcinoma, and potential trea... by haldujai on Saturday July 22, 2023 @02:11PM (#36828366)
I don’t understand your overall point here as this is pretty much how the current system works.

> It is possible to take those probabilities and to talk about the expected number needed to treat (NNT) for a medication, the expected side effect profile, how many people might live and how many might die.

NNT > NNH = efficacy. To calculate these the trials need to be done, which is not the case for experimental therapies as they have undetermined benefits and harms (hence why they’re in trial).

The choice here is between conventional options that have known benefits/harms, however crappy they may be, with something that has unknown values.

Re:I am dying of squamous cell carcinoma, and potential trea... by tux3 on Saturday July 22, 2023 @02:40PM (#36828618)
Trials are done in multiple phases, with a progressively wider population. There is a point where we consider a drug to still be unproven, but safe enough for human trials.

I think that situations like TFA make a compelling case for selectively broadening access, for some drugs and some pathologies. The characterization of a choice between something proven and something with unknown values is too coarse and not a good model.

Clinical trials are very expensive, drug development as a field tends to move forward with what it thinks will have a chance of making it through. While most new drugs indeed fail (the large majority of them), in diseases with very poor prognosis like OP's cancer, I think we would benefit from still looking at the tradeoff as a decision under uncertainty, instead of a complete unknown. Even with less data than we would otherwise want.

Looking at experimental therapies as completely undetermined leads to a binary choice, where considering the supporting evidence that allows those therapies to move forward with experimental trials in the first place is more precise. The counterfactual of not treating patients with poor prognosis being what it is, my overall point is that treating experimental drugs as total unknowns with benefits and harms that cannot be quantified until the full process is finished is not consistent with the knowledge that, even after all trials are completed, this is still a uncertain statistical result, only with slightly more data than before.

Re:I am dying of squamous cell carcinoma, and potential trea... by haldujai on Saturday July 22, 2023 @02:46PM (#36828677)
> While most new drugs indeed fail (the large majority of them), in diseases with very poor prognosis like OP's cancer, I think we would benefit from still looking at the tradeoff as a decision under uncertainty, instead of a complete unknown. Even with less data than we would otherwise want.

Which is literally what just happened with osimertinib for NSCLC. It was approved for clinical use and was implemented without any overall survival data.

Safe for clinical trial means the harms are considered safe, has little to no relevance for efficacy.

Once again you’re ignoring the fact that there are (almost) always alternative treatments that have been proven to prolong life.

No one is offering nothing to poor prognosis patients.

From the blog post:

> Monday I’m starting chemotherapy, but that’s almost certainly going to fail, because a CT scan shows four to six new gross tumors, four in my neck and two, possibly, in my lungs.

In someone with such an aggressive disease everything is almost certainly going to fail, experimental or not. Chemotherapy will buy some time. Who knows what an mRNA treatment will do but there’s certainly no (not little, no) evidence that it will be curative.

Re:I am dying of squamous cell carcinoma, and potential trea... by tux3 on Saturday July 22, 2023 @03:06PM (#36828862)
You're right that there are alternatives, and there is an existing standard of care. I don't think I'm ignoring that. Let me clarify, I am not saying that patients with poor prognosis are being offered nothing. They are being offered standard of care.

I think sticking with standard of care until new drugs have gone through the full, current process may be net negative under the current process, and considering the counterfactual especially for patients with poor prognosis.

Chemoterapy will buy some time with certainty, but in expectations broadening access even slightly means we can gain confidence in the experimental treatments that do work slightly sooner, and that improves the standard of care for everyone. Experimental drugs sometimes do work, and it would be bias to only look at the risks while sweeping aside the potential upside.

Consider what happens a few years from now with the current system and with a system that selectively broadens access in some cases, when the early data seems to support the risk/reward. Even if most new medications fail, the cost of delaying those few therapy that will happen to work is much larger than the risk being paid by the trial population. That's because only a few people participate in trials, but everyone benefits from the results. This is why we have trials at all.

In someone with an aggressive disease such as OP, that person may very likely benefit from having that choice. Today they may choose to buy some time with _relative_ certainty, knowing that chemo has very heavy side effects and that they may not enjoy very much of that remaining time. But they may not choose to try some experimental treatments, even when the risk/reward seems reasonable according to early data, even though that may result in a small chance of success, and certainly data that will help bring therapies quicker to more people.

The benefit of experimental treatment is not just to the individual participating in the experiment. Part of the benefit, that helps justifies the risk, is the idea that a fraction of the treatments will be worthwhile. Slowing down trials is safer in the sense that no one will be responsible for anyone losing their chance at chemo or dying, but it creates the exact kind of invisible deaths in expectation that TFA talks about.

Re:I am dying of squamous cell carcinoma, and potential trea... by haldujai on Saturday July 22, 2023 @03:20PM (#36828967)
Current standard of care includes experimental therapy. What you are describing is once again how novel cancer treatments are being implemented today.

Furthermore, Step 1 of the NCCN treatment guidelines for these kinds of cancers (i.e. advanced and/or poor responders to conventional chemo) is always that the patient is enrolled in a clinical trial.

In this authors case he does not meet inclusion criteria for the therapies he is listing, both trials require systemic therapy with novel PD-1 inhibitors (aka immune checkpoint inhibitors, immunotherapy) which when they work do so fantastically with little side effects.

Per his description he has not tried any systemic therapy yet.

I’m unclear whether he’s lumping chemo with immunotherapy (often the case by non-domain expert patients) but not even Moderna is interested in going from surgery directly to mRNA.

This isn’t the FDA getting in the way. He hasn’t exhausted good treatment options yet to be eligible for unapproved experimental ones. It would absolutely be detrimental to ignore ICIs in an eligible patient in favor of [insert non-approved experimental therapy with no evidence].

I’ve seen far more advanced metastatic H&N SCC survive for years on ICIs in my clinical practice. We don’t know all the specifics of this case but this isn’t nothing/days/weeks vs mRNA as the author is pitching.

Re:I am dying of squamous cell carcinoma, and potential trea... by tux3 on Saturday July 22, 2023 @03:54PM (#36829236)
That's fair, I'll admit I didn't check the inclusion criteria in the case of OP.

I'll take your point, and I appreciate the time you took to write a good response, though I've read about enough examples other than the current article that I feel this may be rejecting a wider pattern on the details of the current submission (but maybe I'm wrong, and they all happened to be incorrect for similar reasons).

But I'd like to hear your thoughts on the broader argument of being more aggressive with trials in general. What sticks with me each time this argument comes up, regardless of the particular situation, is this idea that despite some mechanisms for accelerated approvals, we are still far slower than we could be, if we take into account the number of people saved by bringing therapies sooner.

There is a cost to letting people take dangerous medication. I hate the idea of peddling dubious cures to vulnerable people as much as I'm sure you do. It's the counterfactual that makes the argument, the people who do not receive treatment due to delay seems to vastly outnumber the people harmed by experimental treatments. And the difference seems large enough that it would remain true even if we went much faster. I think that's the strongest objection to the current system.

Re:I am dying of squamous cell carcinoma, and potential trea... by haldujai on Saturday July 22, 2023 @04:21PM (#36829516)
Please note I am speaking only for the world of oncology as that's my practice focus and what I know best.

> But I'd like to hear your thoughts on the broader argument of being more aggressive with trials in general. What sticks with me each time this argument comes up, regardless of the particular situation, is this idea that despite some mechanisms for accelerated approvals, we are still far slower than we could be, if we take into account the number of people saved by bringing therapies sooner.

Everything in medicine is trade-off. On the extremes we can practice with no regulation and have immediate access to treatments without evidence accepting that many patients will be harmed as many new treatments are inferior or require phase IIIs on the other end and minimize harms but accept that delayed care will itself cause harm.

Current practice is somewhere in the middle, depending on various factors like efficacy, risks/harms, and alternatives many treatments enter practice after phase I/II or used off-label for close indications.

I like where we're currently at for oncology and don't think we need to change much in the process. The bigger hurdle is funneling those R&D $ into high yield research and perhaps making the cost of trials easier (e.g. research alliances, IT infrastructure to simplify multi-center studies and patient recruitment, ?active government involvement).

There's always fine tuning of that balance that can be done and some cases will prove things wrong on either side of the argument but generally speaking I think we're close to where we need to be. Definitely better than when we didn't have the current approval process.

> It's the counterfactual that makes the argument, the people who do not receive treatment due to delay seems to vastly outnumber the people harmed by experimental treatments.

I don't think this is true and I have not seen evidence to support this claim. There is ample evidence of failed treatment options or treatment causing more harm than good. An example I'm well-versed in is HIPEC for advanced ovarian/peritoneal cancers (we've been doing this for years and it turns out it doesn't do much other than excessive morbidity) or Y-90 for HCC/colorectal metastases to the liver (first trials negative and we recently found out "oops we've been underdosing this and measuring non-target dosing to the lungs incorrectly") both of which are for palliative patients with no good alternatives.

Going back to osimertinib as the example, the main criticism of earlier TKIs (same class of drug, and even osimertinib for that matter) was that the promise of limited data (progression free survival rather than overall) led some patients to get TKI therapy rather than platinum based chemo which was standard of care and has proven OS benefit. Except when the OS data came out it was an "oops, OS didn't pan out like PFS" and people were harmed.

That these happen in the current system strongly suggest patients have access to experimental therapies and that we're not being overly stringent, or this data wouldn't exist.

I would also say that a large proportion of the patients I've interacted with that have disseminated disease are on some trial for experimental therapy with the caveat that I've only worked at tertiary care cancer centers. It's really not that hard to get enrolled if you meet criteria. I believe the stories we read of access challenges are largely a vocal minority with challenging circumstances or a misunderstanding of treatment options.

Re:I am dying of squamous cell carcinoma, and potential trea... by tux3 on Saturday July 22, 2023 @04:37PM (#36829646)
Thank you. I really appreciate your patience and your careful replies, as well.
Re:I am dying of squamous cell carcinoma, and potential trea... by haldujai on Saturday July 22, 2023 @04:43PM (#36829711)
No problem. I appreciate the discussion, it's good for me (and medicine in general) to be challenged on held beliefs as things tend to devolve insidiously in this field.
Re:I am dying of squamous cell carcinoma, and potential trea... by civilitty on Saturday July 22, 2023 @01:53PM (#36828218)
> Why do we get to decide what is and isn't worth the risk?

It's not their risk to take. Getting a drug to market is a complex process that can be derailed by any number of mistakes ranging from the mundane like improper blood draw during clinical trials to the tragic like accidental deaths that puts public pressure on the FDA to shut it down or spook away investors. Any hiccup in this process can kill it and once a patent expires, the chances of someone bringing that drug to market is almost zero, regardless of its efficacy.

The vast majority of drugs and therapies are developed via private investment and many companies go public before they make even a cent of revenue to fund the clinical trials. Public sentiment is the driving force behind their stock prices because they're literally forbidden from making money until the FDA approves their drug. Lots of them go bankrupt every year before finishing clinical trials or releasing a product and rushing the process is quick ticket there.

Patients don't get to put at risk the decades of good a drug can do because they're desperate and afraid of dying.

Re:I am dying of squamous cell carcinoma, and potential trea... by thedragonline on Saturday July 22, 2023 @04:52PM (#36829805)
I'm not sure removing options from the desperate and dying is a good idea. Those with means will just ignore your concerns and the rest will have _nothing to lose_.
Re:I am dying of squamous cell carcinoma, and potential trea... by EA-3167 on Saturday July 22, 2023 @06:21PM (#36830528)
I can't find it anymore, but there was a paper or maybe study looking into the question of healthcare outcomes for just such "people of means." Iirc there was some interesting data which showed being able to afford doctor shopping and concierge service was sometimes correlated with poor outcomes compared to the standard of care overall. I think it makes sense, the patient can demand what they want and then get it, but they're not necessarily armed with the knowledge or perspective to make the informed decision. If they can afford to find a doctor who values a lot of money over anything else though, they can get it, and that might not work out so well for them.

Michael Jackson, Joan Rivers and Lisa-Marie Presley for example would probably all still be alive if they didn't have the money to simply buy the healthcare they wanted, damn the consequences and cost.

Re:I am dying of squamous cell carcinoma, and potential trea... by sleight42 on Saturday July 22, 2023 @01:42PM (#36828134)
Just "invest more"?

Who does the investing? Not "The Market". The incentive isn't to cure but to treat. The Market wants (repeat) customers.

The government? At least, in the US, we've been dismantling the government's ability to do this since at least Reagan. Even our so-called Liberals aren't pushing hard here. You'd have to look to the "fringe" Progressives within the Democratic Party to even come close.

And why? Because "fuck you, I've got mine" may as well be the national motto of the USA at this point.

People will bristle at this, certainly. Look at Biden: he's done so much!

Biden is no FDR. We need a real social safety net in this country. And, yes, we need a "right to try", even if it means waiving malpractice rights in those cases.

Re:I am dying of squamous cell carcinoma, and potential trea... by nine_k on Saturday July 22, 2023 @02:30PM (#36828509)
Indeed, there's the perverse insensitive to create a repeat customer.

Funnily, an insurance company would push against that, for a final cure. They would like to avoid to pay for repeat treatments.

But the medical insurance in the US is more of a payment scheme, and apparently is not interested in paying less. I bet there is some regulatory loophole, or a government guarantee, that makes it more profitable.

Re:I am dying of squamous cell carcinoma, and potential trea... by GuB-42 on Saturday July 22, 2023 @02:04PM (#36828311)
> The incentive isn't to cure but to treat. The Market wants (repeat) customers.

I am fed up with this argument.

Compared to a recurring treatment, a cure will:

- destroy the competing recurring treatment

- sell particularly well initially, when you still have the patent, potentially at a high price

- not stop the influx of repeat customers, since as long as people are alive, they will need medicine, and people who are now healthy because you cured them will be more likely to have a well paying job that will pay for expensive drugs

If that argument was true, no one would do vaccines, especially considering that most vaccines are not particularly expensive.

Re:I am dying of squamous cell carcinoma, and potential trea... by haldujai on Saturday July 22, 2023 @02:27PM (#36828489)
Agree. I can speak for oncology where the desire is always curative intent treatments. Unfortunately it’s often not possible so we settle for palliative therapy (presumably what GP meant by recurring).

Personally/professionally I think this argument comes from non-experts failing to understand the disease process and therapeutic challenges. I’ve seen no evidence or suggestion in my years of clinical practice that this assertion has a shred of truth behind it.

> If that argument was true, no one would do vaccines, especially considering that most vaccines are not particularly expensive.

While I agree with you this statement does not prove your argument. Vaccines aren’t a good example of funding for curative intent treatments.

The economics behind vaccinations are different as you vaccinate orders of magnitude more patients than would ever get the disease so even if the nefarious assumption is valid the economics may still favor this path.

Re:I am dying of squamous cell carcinoma, and potential trea... by User23 on Saturday July 22, 2023 @02:28PM (#36828496)
Gilead’s hepatitis cure is a real example of this[1], so it’s not some hypothetical. The sales plummeted and wall street dinged them for it.

[1] https://www.investors.com/news/technology/can-gilead-withsta...

Re:I am dying of squamous cell carcinoma, and potential trea... by haldujai on Saturday July 22, 2023 @02:42PM (#36828647)
Wall Street dinged them because Gilead is a one trick pony and the street overestimated revenue, not because Gilead cured HCV rather than just treating it.

Additionally, if their drug didn’t work as well they wouldn’t have gotten away with charging 100k for a course and wouldn’t have made 40B+ in revenue.

Re:I am dying of squamous cell carcinoma, and potential trea... by GuB-42 on Saturday July 22, 2023 @02:59PM (#36828808)
Just read the article until the end.

> Yee, though, says Gilead isn't filling a hole left from its declining HCV unit. It's merely coming down off a "massive bolus of hundreds of thousands of people who came in during the first two years."

> "The drug is still set to do $8 billion in 2017 and is one of the largest drugs in the world. Not exactly a hole," he said.

The Gilead stock is worth 4x today what it was worth in 2012, before they had the cure. It is better than the average "big-pharma" (ex: Pfizer). The stock plateaued because they couldn't follow up, but before you look at the dip, you should look at the massive raise before it.

Re:I am dying of squamous cell carcinoma, and potential trea... by sleight42 on Saturday July 22, 2023 @02:20PM (#36828435)
Vaccines aren't a cure. They require repeat customers. You're making my argument for me.
Re:I am dying of squamous cell carcinoma, and potential trea... by haldujai on Saturday July 22, 2023 @02:30PM (#36828516)
Most vaccines only require 1-3 injections.

This example is poorly chosen for a different reason explained in my comment.

Alternatively, we can look at novel curative intent therapies for cancer like focal ablation or stereotactic radiation.

The recurring customer alternative of chemo/immunotherapy or the conventional surgical option are at least an order of magnitude more expensive.

You won’t find much novel systemic therapy that’s curative intent because it’s really hard (?impossible) to do, not because the system wants to make more money slowly killing patients.

Re:I am dying of squamous cell carcinoma, and potential trea... by matteoraso on Saturday July 22, 2023 @01:54PM (#36828223)
>How often do these drugs, etc turn out to effective?

This is a big point a lot of people ignore. I feel terrible for the author, but if there hasn't been a single drug invented so far that has any real chance of curing him, it's extremely unlikely that this one out of reach drug is going to be the drug that can save his life. I don't really know much about medicine, but I'm pretty sure that progress is usually incremental as well, so you start out with drugs that cure some patients and work from there instead of having some massive breakthrough.

Re:I am dying of squamous cell carcinoma, and potential trea... by jasode on Saturday July 22, 2023 @01:58PM (#36828261)
>I think the solution is to invest more into medical research now,

The author is arguing that terminally ill people (with a few months left to live) -- like him -- would be willing participants in trials to help medical research. They already know that mRNA drug or whatever likely won't cure them. It's possible some new scientific knowledge of the drugs' effects can still be gained even when it doesn't cure them.

Given the realistic odds, the primary purpose (from society's perspective) of letting of terminal patients participating in unproven drug trials would be medical research rather than "Hail Mary cures". From the patient's perspective, of course they hope it improves their health.

Re:I am dying of squamous cell carcinoma, and potential trea... by mlyle on Saturday July 22, 2023 @02:33PM (#36828546)
There's a lot of problems with it, though. Even if advancing medical research was the main goal-- ad hoc use in dying patients provides unclear data. Medical research wants clear inclusion criteria, metrics, reduced statistical noise from similar patients, predeclared outcome measures, and economies of scale in running trials.

We already let terminal patients participate in medical research, but only inviting patients at times and meeting criteria that optimizes the research (and where IRBs have found it to be ethical).

But terminally-ill patients push for inclusion beyond this: to be dosed when there is not an active trial, or to be dosed when they are so sick that the outcome would be difficult to interpret or compare, etc. This isn't for medical research, this is for self-preservation.

Re:I am dying of squamous cell carcinoma, and potential trea... by jasode on Saturday July 22, 2023 @02:48PM (#36828706)
>There's a lot of problems with it, though. [...] Medical research wants clear inclusion criteria, [...] , but only inviting patients at times and meeting criteria that optimizes the research [...] But terminally-ill patients push for inclusion beyond this: to be dosed when there is not an active trial, [...]

Your objections are sensible but that's beyond the scope of this author's argument. I'm just taking author's following comment at face value: ">The FDA was loathe to approve initial mRNA human trials, even when those trials would have been full of people like me: those who are facing death sentences anyway."

If it's the drug researchers who don't want the author as a test subject, that's understandable. But he's arguing the _FDA_ shouldn't be the one blocking his participation.

For the situations where there's "no active trial" caused by the FDA not greenlighting the experiments, then of course, the complaint will be that "terminally ill patients want to participate in trials that don't exist". That's sort of a circular argument -- caused by the FDA.

Again, if there's no active trial because the medical researchers themselves are not yet ready, that's understandable. But if the drug scientists are ready but the FDA is not, that's a different issue and it's the focus of the author's essay.

All that said, I don't know how much scientific progress the FDA holds back because of "safety". I'm just trying to explain the author's position.

Re:I am dying of squamous cell carcinoma, and potential trea... by mlyle on Saturday July 22, 2023 @03:01PM (#36828828)
> I'm just taking author's following comment at face value

Plenty of mRNA human trials of cancer treatment are in progress. Indeed, as he stated, he wants into two that are underway, but that he is probably too far along for. He wishes that they had been greenlit even earlier and perhaps made their way to be approved drugs that he could just be given by his local doctor.

> For the situations where there's "no active trial" caused by the FDA not greenlighting the experiments,

There's compassionate use exceptions for circumstances like this.

The big thing is, there's two big bars to cross with getting a trial together:

- You probably want to be doing human research in a way that will produce evidence that will convince the FDA to grant you approval. (Hence, drug companies often are nervous that compassionate use will pollute their data).

- The FDA wants to protect human subjects, and if there's a drug that results in 15% survival for a year, vs. 5% for doing nothing and ???% for your new experimental treatment: they want that drug to be tested as part of a protocol that minimizes potential harms, not to randomly replace the 15% survival treatment. Most experimental treatments end up failing.

Re:I am dying of squamous cell carcinoma, and potential trea... by haldujai on Saturday July 22, 2023 @03:12PM (#36828908)
> Indeed, as he stated, he wants into two that are underway, but that he is probably too far along for.

The author is incorrect on this, he’s not too far along but he does not meet inclusion criteria for either of the studies he cited as both require systemic therapy.

mRNA is not being pitched or tested as a first-line mono therapy by Moderna. I’m not sure why the author is jumping the gun here and ignoring approved systemic treatment options.

Re:I am dying of squamous cell carcinoma, and potential trea... by mlyle on Saturday July 22, 2023 @03:25PM (#36829011)
He may not be too far along from the standpoint of inclusion criteria; rather he believes he is likely to die before he is able to join the study.
Re:I am dying of squamous cell carcinoma, and potential trea... by haldujai on Saturday July 22, 2023 @03:28PM (#36829036)
I’m ignoring that part because it is nearly impossible to prognosticate prior to initiation of systemic therapy, with the exception of some phenotypes but we don’t have the pathology report in this case.

My point is that he doesn’t even meet the inclusion criteria for these studies, regardless of aggressiveness. This has nothing to do with the FDA, he can’t join the studies because Moderna doesn’t want to study him at this point and not because he won’t survive long enough to enroll.

Whether or not his prognosis statement is correct.

Re:I am dying of squamous cell carcinoma, and potential trea... by haldujai on Saturday July 22, 2023 @03:01PM (#36828824)
Excellent explanation, parent is also correct. I think the author’s position is misinformed.

The FDA doesn’t hold back researchers on inclusion/exclusion criteria.

Inclusion for the Moderna trial he linked to:

> Must have primary refractory or acquired secondary resistance to prior immune checkpoint treatments. Primary refractory is defined as prior exposure to anti-programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) antibody for at least 6 weeks but no more than 6 months with demonstration of progression on 2 separate scans at least 4 weeks apart but no more than 12 weeks apart and progression occurring within 6 months after first dose of anti-PD-1 antibody. Acquired secondary resistance must have confirmed objective response or prolonged stable disease (SD) (>6 months), followed by disease progression in the setting of ongoing treatment and confirmed progression on scans at least 4 weeks apart.

Exclusion criteria:

> Participant has received treatment with prohibited medications (that is, concurrent anticancer therapy including other chemotherapy, radiation [local radiation for palliative care is permitted with approval from the Sponsor]…

From the description of the patient’s treatment course it sounds like he had curative intent radiation (given he subsequently had surgery) and would probably not meet this study’s criteria making the limiting factor Moderna not the FDA.

He also doesn’t mention whether he’s starting immunotherapy/checkpoint inhibitors (or his tumor status) and may be lumping immunotherapy with chemotherapy which is a good new treatment option and would typically be offered if eligible. Definitely better than being enrolled in a dose study and in fact is required by Moderna.